(Q42168997)

17 October 2017

title

Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders (English)

1 reference

17 October 2017

1 reference

1 reference

4

Levander S

1 reference

17 October 2017

Eberhard J

1

1 reference

17 October 2017

Lindström E

series ordinal

2

1 reference

17 October 2017

Holstad M

series ordinal

3

1 reference

17 October 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Acta Psychiatrica Scandinavica

17 October 2017

published in

1 reference

17 October 2017

volume

115

1 reference

17 October 2017

issue

4

1 reference

17 October 2017

page(s)

268-276

1 reference

Dopamine Nerve Terminals in the Rat Limbic Cortex: Aspects of the Dopamine Hypothesis of Schizophrenia

17 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

Sexual dysfunction with psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

Osteoporosis in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

Elevation of prolactin levels by atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

Gender differences in age at onset of schizophrenia. An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

Effects of perphenazine enanthate injections on prolactin levels in plasma from schizophrenic women and men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

Sexual dysfunction and antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

Beta cell proliferation and growth factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

Gender differences in the course of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00897.X

10.1111/J.1600-0447.2006.00897.X

21 January 2018

Identifiers

DOI

1 reference

17 October 2017

1 reference